Zolbetuximab has demonstrated significant therapeutic potential in the treatment of malignant tumors such as gastric cancer. Currently, zolbetuximab has not yet been launched in China. This article pr...
Zolbetuximab has demonstrated significant therapeutic potential in the treatment of malignant tumors such as gastric cancer. Currently, zolbetuximab has not yet been launched in China. This article pr...
Zolbetuximab (brand name: VYLOY) is a cytolytic antibody targeting Claudin 18.2 (CLDN18.2). It was first approved for marketing in the United States in 2024. It is indicated for the first-line treatme...